Table 2 S. mansoni prevalence and intensity of infection in the community adults before and after treatment (cross-sectional data)

57.4 (54.1–60.6) (n = 903)

34.7 (31.1–38.2) (n = 689)

9.8 (6.9–12.8) (n = 397)

82.9%

43.1 (35.9–50.3) (n = 181)

16.1 (10.2–22.0) (n = 149)

6.1 (1.7–10.6) (n = 114)

85.8%

65.6 (60.2–70.9) (n = 302)

42.9 (35.2–50.7) (n = 156)

17.8 (6.6–28.9) (n = 45)

72.9%

57.6 (52.9–62.4) (n = 420)

38.5 (33.7–43.4) (n = 384)

10.1 (6.3–13.9) (n = 238)

82.5%

64.6 (60.2–69.1) (n = 441)

40.1 (34.5–45.7) (n = 294)

9.3 (5.3–13.2) (n = 205)

85.6%

48.2 (43.4–53.0) (n = 413)

28.5 (23.3–33.7) (n = 288)

9.9 (5.7–14.2) (n = 191)

79.5%

251.6 (213.7–289.6) (n = 903)

80.4 (61.1–99.7) (n = 689)

19.6 (4.9–34.3) (n = 397)

92.2%

42.6 (39.4–45.9) (n = 385)

65.3 (61.7–68.9) (n = 450)

90.2 (87.3–93.1) (n = 358)

-

23.7 (20.9–26.5) (n = 214)

19.3 (16.4–22.3) (n = 133)

6.8 (4.3–9.3) (n = 27)

-

16.8 (14.4–19.3) (n = 152)

10.2 (7.9–12.4) (n = 70)

2.0 (0.6–3.4) (n = 8)

-

16.8 (14.4–19.3) (n = 152)

5.2 (3.6–6.9) (n = 36)

1.0 (0.0–2.0) (n = 4)

-

67.6 (46.3–89.0) (n = 181)

31.0 (9.4–52.5) (n = 149)

2.5 (0.1–4.8) (n = 116)

96.3%

411.2 (321.6–500.7) (n = 302)

131.9 (74.9–189.0) (n = 156)

62.0 (0.0–167.6) (n = 48)

84.9%

216.2 (169.7–262.6) (n = 420)

78.7 (54.5–102.9) (n = 384)

18.4 (5.9–30.8) (n = 247)

91.5%

346.9 (285.0–408.8) (n = 441)

101.8 (65.8–137.9) (n = 294)

19.6 (0.0–44.4) (n = 205)

94.3%

154.9 (107.6–202.2) (n = 413)

69.2 (42.9–95.6) (n = 288)

19.7 (4.6–34.9) (n = 191)

87.3%